UroGen Pharma heads into August earnings with a striking divergence at its core — short sellers are barely moving despite a 40% rally that has pushed the stock near analyst targets.
The most arresting feature of this setup is how little the short position has responded to the price surge. Short interest holds at 14.5% of free float, essentially flat on the week and up less than 1% on the month. That is a meaningful level — roughly one in seven freely traded shares is sold short — yet it is not one where the borrow market shows any stress. Availability is loose at nearly 458%, meaning there are more than four shares available to borrow for every one currently lent out, and cost to borrow has actually fallen around 30% over the past month to just 0.44%. The lending setup offers shorts no particular reason to panic, even as the stock climbs. The 52-week trough in availability hit 3.7%, so the current reading is far from any squeeze territory.
Options traders are turning noticeably more bullish than usual. The put/call ratio has dropped to 0.44, nearly two standard deviations below its 20-day average of 0.50, and is tracking toward the lower end of its one-year range of 0.18–0.89. That shift in options positioning has coincided precisely with the stock's acceleration — through late June the PCR ran closer to 0.55, and it has ground lower each week since. The direction of travel in the options market and the direction of travel in price are, for now, aligned.
The Street is unanimously constructive but only modestly ahead of where the stock now trades. HC Wainwright raised its target to $45 in May and has reiterated that level twice since, while Oppenheimer lifted its target to $40 after Q1 results. D. Boral Capital holds a $33 target, now below the current price of $37.75, making it effectively a drag on the consensus mean of $37.13. That consensus is barely a rounding error below the current price — the rally has largely consumed the implied upside that existed at the start of the year. The bull case rests on the pipeline: UGN-103 and UGN-104, and the durability of Jelmyto revenues, where 1-year sales growth is running near 53%. The bear case is sharper — a Teva settlement reportedly preserved only around 10% of Jelmyto's exclusivity window, and ZUSDURI faces generic competition risk before its 2031 patent expiry. EV/EBITDA has compressed from near 137x at the start of June to 94.6x now, reflecting the earnings improvement, but a PE still north of 300x is not a cheap stock.
Institutional activity around the Q1 period showed fresh money coming in. Kynam Capital Management entered with a new position of 2.25 million shares, Opaleye added 1.16 million, and Frontier Capital built by 532,000. BlackRock added 244,000 shares through June. On the other side, the CMO Mark Schoenberg has sold shares three times since early May — $300,000 in May, $143,000 in early June, and $350,000 on June 22 — a consistent pattern of realising gains into the rally at successively higher prices. The net insider position over 90 days is technically positive at 25,222 shares, but that is entirely award-driven; every cash transaction in the window has been a sell.
Q2 results are due August 10. The last three earnings prints produced one-day moves of +4.7%, +1.4%, and +11.6% respectively, with the five-day drift running from -2.8% to +29.8% — a wide range that reflects how binary this story can be. What the August print needs to address is not just the revenue trajectory but the Jelmyto exclusivity timeline and whether the pipeline milestones justify maintaining short interest at 14.5% of the float with a stock that has already moved 40% in a month.
See the live data behind this article on ORTEX.
Open URGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
